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Abstract
Aims/hypothesis We examined whether candidate biomarkers in serum or urine can improve the prediction of renal disease
progression in type 1 diabetes beyond prior eGFR, comparing their performance with urinary albumin/creatinine ratio (ACR).
Methods From the population-representative Scottish Diabetes Research Network Type 1 Bioresource (SDRNT1BIO) we
sampled 50% and 25% of those with starting eGFR below and above 75 ml min−1 [1.73 m]−2, respectively (N = 1629), and with
median 5.1 years of follow-up. Multiplexed ELISAs and single molecule array technology were used to measure nine serum
biomarkers and 13 urine biomarkers based on our and others’ prior work using large discovery and candidate studies.
Associations with final eGFR and with progression to <30 ml min−1 [1.73] m−2, both adjusted for baseline eGFR, were tested
using linear and logistic regression models. Parsimonious biomarker panels were identified using a penalised Bayesian approach,
and their performance was evaluated through tenfold cross-validation and compared with using urinary ACR and other clinical
record data.
Results Seven serum and seven urine biomarkers were strongly associated with either final eGFR or progression to <30 ml min−1
[1.73 m]−2, adjusting for baseline eGFR and other covariates (all at p<2.3 × 10−3). Of these, associations of four serum
biomarkers were independent of ACR for both outcomes. The strongest associations with both final eGFR and progression to
<30 ml min−1 [1.73 m]−2 were for serum TNF receptor 1, kidney injury molecule 1, CD27 antigen, α-1-microglobulin and
syndecan-1. These serum associations were also significant in normoalbuminuric participants for both outcomes. On top of
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baseline covariates, the r2 for prediction of final eGFR increased from 0.702 to 0.743 for serum biomarkers, and from 0.702 to
0.721 for ACR alone. The area under the receiver operating characteristic curve for progression to <30 ml min−1 [1.73 m]−2
increased from 0.876 to 0.953 for serum biomarkers, and to 0.911 for ACR alone. Other urinary biomarkers did not outperform
ACR.
Conclusions/interpretation A parsimonious panel of serum biomarkers easily measurable along with serum creatinine may
outperform ACR for predicting renal disease progression in type 1 diabetes, potentially obviating the need for urine testing.
Keywords Clinical science . Epidemiology .Metabolomics . Nephropathy . Proteomics
Abbreviations
ACR Albumin/creatinine ratio
AUC Area under the receiver operating characteristic
curve
CD27 CD27 antigen
CKD Chronic kidney disease
CKD-EPI Chronic Kidney Disease Epidemiology
Collaboration
DKD Diabetic kidney disease
ESRD End-stage renal disease
IQR Interquartile range
KIM-1 Kidney injury molecule 1
MCP-1 Monocyte chemotactic protein 1
SIMOA Single molecule array
TNFR1 TNF receptor 1
Introduction
To facilitate the early identification of those most at risk of
decline in future renal function, most clinical guidelines
recommend the use of regular serum creatinine measurement
and equations such as the Chronic Kidney Disease
Epidemiology Collaboration (CKD-EPI) or Modification of
Diet in Renal Disease (MDRD) equations for estimation of
GFR [1]. The best predictor of future end-stage renal disease
(ESRD) is the current eGFR and past eGFR trajectory [2]. As
we recently reviewed [3], while serum cystatin C-based eGFR
equations have also been proposed, at present creatinine-
based equations remain the most widely used for estimating
GFR [4–8]. Guidelines also advocate regular urinary testing
for albumin/creatinine ratio (ACR) since there is extensive
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evidence that albuminuria is a strong risk factor for progres-
sion of diabetic kidney disease (DKD). However, it has been
widely discussed that ACR lacks specificity and sensitivity for
progressive decline in eGFR. For example, a poor positive
predictive value was reported, with only about a third of those
with microalbuminuria having progressive renal function
decline [9]. Albumin excretion also had low sensitivity in that
only about half of those with progressive renal function
decline were albuminuric [9]. A further practical limitation
of ACR is that obtaining urine samples for ACR adds to clinic
workload and can be inconvenient and difficult for people
with diabetes, resulting in suboptimal uptake. In Scotland,
for example, while 86% of those with type 1 diabetes had
eGFR in the past year, only 62% had ACR measured [10].
An important question is therefore whether any other prog-
nostic biomarkers can improve on ACR or even replace it for
predicting renal function decline. In a recent paper [11] we
reported a large-scale discovery experiment where we
assessed 297 biomarkers in two type 1 diabetes cohorts with
starting eGFRs of 75 ml min−1 [1.73 m]−2 or less. We found
many highly statistically significant biomarker associations
with future eGFR, and that prediction of future eGFR using
ACR and baseline eGFR could be improved with biomarkers.
However, most of the improvement could be achieved by
measuring just serum kidney injury molecule 1 (KIM-1) and
CD27 antigen (CD27), a member of the TNF superfamily.
Following on from that study, we extended the evaluation
to (1) include study participants with higher starting eGFRs;
(2) measure the best biomarkers from our first study i.e. KIM-
1 and CD27, but also measure new candidate biomarkers
chosen from recent reports from large well-conducted studies;
and (3) evaluate a more sensitive serum KIM-1 assay using
single molecule array (SIMOA) technology, hypothesising
that it would be detectable before microalbuminuria in those
progressing to renal function decline. The focus of our analy-
sis was to assess how well these biomarkers predict future
eGFR and whether they could outperform or add to the predic-
tion gained with ACR across a wide range of initial eGFRs.
Methods
Participants The Scottish Diabetes Research Network Type 1
Bioresource (SDRNT1BIO) [12] is a prospective cohort study
comprising 6127 people with a clinical diagnosis of type 1
diabetes mellitus, representing 25% of all adults with type 1
diabetes in Scotland, recruited between December 2010 and
November 2013. On the day of recruitment (which we refer to
as the study day or biosample date), clinical measurements
and blood and urine samples were obtained in which serum
creatinine and urinary ACR were measured. From electronic
healthcare records we extracted routine health-related data
retrospective and prospective to study day, as described [12].
For this study we selected 1629 individuals with eGFR
30 ml min−1 [1.73 m]−2 or above at study biosample date
and with at least three prospective eGFR determinations over
a period of at least 2 years or incident ESRD. These were a
random sample of 50% and 25% of those with starting eGFR
below and above 75 ml min−1 [1.73 m]−2, respectively.
The study was performed in accordance with the
Declaration of Helsinki; all participants gave their written
consent and the study protocol was approved by the local
ethics and data governance committee.
Renal outcomes and covariate data eGFRwas calculated with
the CKD-EPI equation [13] using serum creatinine values
directly measured and retrieved retrospectively and prospective-
ly from medical records. These excluded readings concurrent
with hospital admissions. A summary measure of the historical
eGFR was obtained by computing a weighted average of all
retrospective eGFR records for each person, with weights
inversely related to the amount of time leading to the biosample
date. Participants with no retrospective eGFR data had their
historical eGFR imputed to study day eGFR. Final eGFR was
defined as the median eGFR reading of the last 6 months of
follow-up. Initiation of renal replacement therapy was consid-
ered to indicate an achieved eGFR of 10 ml min−1 [1.73 m]−2
and all subsequent readings were censored. The decline of renal
function was estimated by fitting a simple linear regression
model to the serial prospective eGFR determinations of each
person. We also defined binary clinically significant progression
categories of progression to <30 and <45 ml min−1 [1.73 m]−2.
ACR was measured in paired urine samples with the first
taken at study day and the second several days later using the
ADVIA 2400 immunoturbidimetric method for albumin and
the ADVIA 2400 enzymatic method for creatinine (Siemens,
Munich, Germany). These data were used for adjusting for
ACR in the analyses here. In addition, longitudinal urinary
ACR data were captured from the routine clinical laboratory
data. Clinical record data close to study day were highly corre-
lated (r = 0.73) with the direct measurement. At any time
point, albuminuric status was defined based on the most recent
available albuminuria measurement provided there was no
contradictory record of that stage in the preceding or subse-
quent 90 days; i.e. someone who transited from normo- to
microalbuminuria but then had another normoalbuminuria
measurement within 90 days was assigned as having been
normoalbuminuric across that period, such that transient
changes in albuminuria readings were ignored. Participants
were classified as normo-, micro- or macroalbuminuric
according to their ACR falling in the intervals 0–3.39, 3.39–
33.9 or above 33.9 mg/mmol, based on two out of three
consecutive measurements before baseline.
Retrospective and prospective covariate data including
drug exposures were obtained from the electronic healthcare
record SCI-Diabetes as described previously [12].
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Biomarkers measured and analysed Serum and urine
biomarkers were measured on samples stored at −80°C with
no prior freeze/thaw cycles. The assay methods used and the
quality control performance are summarised in electronic
supplementary material (ESM) Table 1. The candidate
biomarkers were chosen either because we had already shown
these proteins to be predictive of eGFR decline at chronic
kidney disease (CKD) stage 3 or worse (serum KIM-1,
CD27, α-1-microglobulin, thrombomodulin) or because they
were reported from other well-conducted studies as predictive
of renal disease progression (EGF and its ratio to monocyte
chemotactic protein 1 [MCP-1], EGF receptor, cystatin C,
macrophage inhibitory protein, matrix metalloproteinase 8,
TNF receptor 1 [TNFR1]) or as strong candidates from known
biology of DKD (syndecan-1), or because they are routinely
measured on the same multiplex panel as a candidate (the
remainder).
We used a combination of assays using (1) the Luminex
platform (Austin, TX, USA) at the Clinical Laboratory
Improvement Amendments (CLIA)-certified Myriad RBM
laboratory (Austin, TX, USA); (2) a high-sensitivity SIMOA
assay for KIM-1 at Myriad RBM that we had found detected
KIM-1 in samples KIM-1 negative on their standard Luminex
assay; (3) R&D Systems (Minneapolis, MN, USA) Luminex
assay at the Immunoassay Biomarker Core Laboratory,
University of Dundee (Dundee, UK).
Intraclass correlations were computed over 48 blinded
duplicate aliquots to evaluate the reproducibility of the
measurements obtained. Biomarkers were excluded from
the analysis if their intraclass correlation was less than
0.4, or if over 99% of the readings in the dataset were
identical due to falling below the detection threshold.
Accordingly, nine serum and 13 urinary biomarkers were
included in the final analyses.
Values below the detection limit were imputed to half the
detection threshold. All urine biomarkers were normalised to
urinary creatinine.
Univariate analysis To test for associations with renal
outcomes, biomarkers were evaluated independently in
linear models for final eGFR and logistic regression
models for progression adjusted for age, sex, diabetes
duration, study day eGFR and length of follow-up (basic
covariates). To allow comparison with ACR, we reran the
basic and biomarker models including ACR at biosample
date. We further adjusted models for BMI, systolic BP,
diastolic BP, HbA1c, HDL-cholesterol, total cholesterol,
smoking status and a weighted summary of prior eGFR
from retrospective records (full covariates). Prior to fitting
models, all continuous covariates and biomarkers were
Gaussianised and standardised to zero mean and unit stan-
dard deviation. Associations were declared significant at
Bonferroni-corrected p = 0.05/22 = 2.3 × 10−3.
Construction of parsimonious panels of biomarkersUrine and
serum biomarker sets were modelled independently from each
other. As previously described [11], we adopted a Bayesian
modelling approach based on hierarchical shrinkage priors, in
which the clinical covariates used to control for confounding
in the models were assigned a weakly informative Gaussian
prior (which induces some regularisation as in ridge regres-
sion), while biomarkers were penalised through the
regularised horseshoe prior (which heavily shrinks regression
coefficients toward zero unless they are informative) to
promote sparsity [14]. A similar approach was also adopted
elsewhere for biomarker selection in the context of type 2
diabetes mellitus [15]. The hierarchical shrinkage approach
was implemented using the Stan Bayesian inference frame-
work [16], which uses Markov chain Monte Carlo (MCMC)
to sample the posterior distribution of the parameters given the
data and the model. The specific models implemented are
available in the R package hsstan (version 0.6: https://
CRAN.R-project.org/package=hsstan).
We evaluated the predictive performance of models on
withdrawn data using tenfold cross-validation. For each set
of baseline covariates used, we reported the difference in
log-likelihood (computed on the observations withdrawn for
testing from tenfold cross-validation) between the model with
baseline covariates and biomarkers and the model including
only the clinical covariates. For models of achieved eGFR we
computed the r2 as the squared Pearson correlation coefficient
between observed and predicted outcome on the test folds. For
models of progression, we reported the area under the receiver
operating characteristic curve (AUC) and the expected infor-
mation for discrimination, Λ, expressed in bits [17]. This
measure quantifies the gain in information that a set of
biomarkers provides over and beyond the baseline clinical
covariates. The expected information for discrimination was
computed with the R package wevid (version 0.6.2: https://
CRAN.R- project.org/package=wevid).
To recover a parsimonious model, we then applied projec-
tion predictive variable selection [18]. This approach is based
on projecting the high-dimensional draws from the posterior
of the model containing all biomarkers (full model) onto
lower-dimensional subspaces corresponding to sparse candi-
date submodels [19, 20]. Predictions made by each candidate
submodel are compared with those obtained by the full model:
their discrepancy is evaluated using the Kullback–Leibler
divergence, which measures the information lost when a
smaller submodel is used to approximate a more complex
one. By recursively choosing in a forward-selection fashion
the submodel that minimises the Kullback–Leibler divergence
from the full model, one can construct a series of candidate
models of growing complexity. We evaluated each candidate
model in terms of its relative contribution towards the perfor-
mance of the full model, and plotted the relative explanatory
power obtained by biomarker panels of different sizes.
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Results
Participant characteristics Table 1 reports the summary char-
acteristics of those included stratified by CKD stage. The medi-
an (interquartile range [IQR]) of follow-up was 5.1 (4.4, 5.7)
years. For the evaluation of progression status there were a
median (IQR) of 9 (6, 14) measurements of eGFR prospective-
ly. The median change in eGFR was a fall of 0.8 ml min−1
[1.73 m]−2 per year. Overall, 41 and 74 participants, respective-
ly, progressed to <30 and <45mlmin−1 [1.73m]−2 (correspond-
ing to 2.5% and 4.7% of participants not already below these
thresholds). Among the 1404 normoalbuminuric individuals at
baseline, 23.1% developed albuminuria during follow-up.
Biomarkers explored ESM Table 1 shows the median, IQR
and range of the biomarkers analysed in this study. All candi-
date biomarkers showed good intraclass correlation coeffi-
cients (≥0.75) when measured on blinded duplicate samples.
ESM Table 2 lists the biomarkers that were excluded from the
analysis.
The correlation matrix for the biomarkers ordered by hier-
archical clustering is shown in Fig. 1. Four distinct clusters are
seen; for example, we see that cystatin C is moderately corre-
lated with α-1-microglobulin and clusterin, but only weakly
correlated with other biomarkers. TNFR1 and CD27 were
very strongly correlated with each other and moderately corre-
lated with KIM-1.
Table 1 Participant characteristics at study day stratified by CKD stage
Covariate Missing G1 (n = 835) G2 (n = 601) G3 (n = 191) All (N = 1629)
Main characteristics
Age (years) – 41.4 (30.4, 49.8) 54.8 (46.0, 63.5) 63.6 (55.3, 71.1) 48.3 (37.9, 59.2)
Sex (female), % – 41.9 55.2 57.6 48.6
Diabetes duration (years) – 19.0 (10.2, 28.3) 25.4 (16.5, 36.1) 32.1 (21.1, 42.4) 22.4 (12.7, 33.1)
Observability
Retrospective study length (years) – 5.4 (4.5, 6.0) 5.5 (5.0, 6.2) 5.5 (5.1, 6.0) 5.4 (4.8, 6.1)
Length of follow-up (years) – 5.0 (4.3, 5.6) 5.2 (4.6, 5.7) 5.3 (4.5, 5.9) 5.1 (4.4, 5.7)
Retrospective creatinine readings (n) – 9 (6, 14) 12 (9, 18) 16 (10, 24) 11 (7, 17)
Prospective creatinine readings (n) – 8 (5, 11) 11 (7, 15) 15 (9, 24) 9 (6, 14)
Kidney function
ACR (mg/mmol) 21 0.4 (0.2, 0.8) 0.4 (0.3, 1.4) 0.9 (0.4, 4.7) 0.4 (0.2, 1.1)
ACR category (normo/micro/macro), 21 91.9/7.1/1.1 85.9/10.2/3.9 71.7/15.8/12.5 87.3/9.2/3.5
Prevalent micro- or macroalbuminuria, % – 8.1 14.1 28.8 12.8
Incident micro- or macroalbuminuria, % – 16.9 21.1 28.8 19.9
eGFR (ml min−1 [1.73 m]−2) – 104.4 (96.5, 114.6) 74.1 (68.0, 81.8) 51.1 (43.1, 56.0) 90.7 (70.1, 104.9)
Weighted historical eGFR (ml min−1 [1.73 m]−2) 115 107.6 (99.1, 116.6) 83.2 (76.6, 91.2) 61.3 (54.5, 70.6) 93.1 (79.2, 107.9)
Prospective eGFR slope (ml min−1 [1.73 m]−2 year−1) – −0.7 (−2.1, 0.7) −0.7 (−2.7, 0.7) −1.3 (−3.5, 0.7) −0.8 (−2.5, 0.7)
Other covariates
HbA1c (mmol/mol) 3 70 (62, 81) 68 (60, 78) 68 (60, 80) 69 (61, 80)
HbA1c (%) 3 8.6 (7.8, 9.6) 8.4 (7.6, 9.3) 8.4 (7.6, 9.5) 8.5 (7.7, 9.5)
HDL-cholesterol (mmol/l) 54 1.5 (1.2, 1.8) 1.6 (1.3, 1.9) 1.5 (1.2, 1.9) 1.5 (1.2, 1.8)
LDL-cholesterol (mmol/l) 863 2.5 (2.0, 3.0) 2.3 (1.9, 2.9) 2.0 (1.6, 2.4) 2.4 (1.9, 2.9)
Total cholesterol (mmol/l) 21 4.6 (4.0, 5.2) 4.6 (4.0, 5.1) 4.2 (3.7, 4.9) 4.5 (4.0, 5.2)
BMI (kg/m2) 9 26.0 (23.3, 29.5) 26.9 (24.5, 30.1) 27.1 (24.0, 31.0) 26.6 (23.8, 29.9)
Diastolic BP (mmHg) 6 75 (68, 81) 76 (68, 81) 70 (63, 80) 75 (68, 81)
Systolic BP (mmHg) 6 128 (119, 137) 133 (123, 146) 137 (124, 148) 130 (120, 141)
Ever smoker, % – 61.9 65.2 72.3 64.3
On any anti-hypertensive treatment, % – 28.1 58.7 85.9 46.3
On ACEi or ARB, % – 26.1 52.9 77.5 42.1
We report frequency (as %) for categorical variables and median (IQR) for continuous variables
CKD stages are defined according to ranges of eGFR in ml min−1 [1.73 m]−2 : G1: >90; G2: 60–90; G3: 30–60
Participants at stage G4 (eGFR= 15–30; n = 2) are not reported as a separate column
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker
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Univariate associations with final eGFR Seven serum and six
urine biomarkers, including the ratio of urinary EGF to MCP-
1, were strongly associatedwith final eGFR inmodels adjusted
for basic covariates including baseline eGFR (all at p<2.3 ×
10−3; Table 2). Of these, nine remained significantly associated
with final eGFR after further adjustment for ACR at biosample
date. The most strongly associated biomarkers, TNFR1, KIM-
1, CD27, syndecan-1, α-1-microglobulin and urinary EGF/
MCP-1 ratio, were also significantly associated with final
achieved eGFR when restricted to those normoalbuminuric at
biosample date and even when adjusted for ACR in this
normoalbuminuric range (data not shown). Furthermore, other
than α-1-microglobulin, these biomarkers were also highly
significantly associated with final eGFR at follow-up adjusted
for ACR at baseline when restricted to those with eGFR
≥90 ml min−1 [1.73 m]−2 at baseline (data not shown). We
confirmed that the associations were similar when adjusted
for use of ACE inhibitors or angiotensin receptor blockers.
Using progression status to <30 or <45 ml min−1
[1.73 m]−2 as the outcome, a very similar pattern was seen
for serum biomarkers (ESM Tables 3 and 4). For example,
adjusted for basic covariates and ACR, the odds of progres-
sion to <30mlmin−1 [1.73m]−2 were 5.80-fold for every 1 SD
in Gaussianised TNFR1, and 2.05-fold per SD of KIM-1
(ESM Table 3). Among the urinary biomarkers, EGF/MCP-
1 ratio was associated with progression, but when adjusted for
ACR the association remained significant for progression to
<45 but not <30 ml min−1 [1.73 m]−2. When restricted to those
with normo- or microalbuminuria at baseline, a very similar
pattern of association with progression was seen. Among
those with macroalbuminuria at baseline, significant associa-
tions with outcomes were not found, but the sample size was
very small for testing this.
Panels of biomarkers for predicting eGFRTable 3 summarises
the cross-validated performance of the linear regression models
for prediction of final eGFR using all of the serum or urine
biomarkers (in models with hierarchical shrinkage priors) on
top of clinical covariates, with and without further inclusion of
ACR at biosample date. Starting from basic covariates, the r2 for
prediction of final eGFR increased from0.702 to 0.743 for serum
and to 0.721 for urine biomarkers, compared with an increase to
0.722 for ACR alone. Thus, the serum biomarkers alone outper-
form ACR alone. As shown in Table 3, the model including
serum biomarkers with ACR is better than ACR alone.
Similarly, from Table 4 the AUC for progression to
<30 ml min−1 [1.73 m]−2 was 0.911 using ACR with basic
covariates, but was 0.953 with serum biomarkers and basic
covariates, and did not increase further after adding ACR to
serum biomarkers. Using the expected information for
discrimination, Λ, Table 4 shows that serum biomarkers
contain almost one extra bit of information for the prediction
of progression to <30 ml min−1 [1.73 m]−2 than does ACR
(4.06 vs 3.23 bits).
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Fig. 1 Correlation matrix
ordered by hierarchical clustering.
A1Micro, α-1-microglobulin;
Cys-C, cystatin C; GF, growth
factor; HB, heparin-binding;
MMP8, matrix metalloproteinase-
8; PLGF, placenta growth factor;
SDC1, syndecan 1
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The same conclusion is reached using progression to
<45 ml min−1 [1.73 m]−2, and also when restricted to those
with normo- or microalbuminuria at baseline. Among those
with macroalbuminuria, however, there was no evidence of
serum biomarkers outperforming or improving prediction
beyond ACR. There was no evidence of urinary biomarkers
outperforming ACR for progression in any stratum.
By applying the projection predictive variable selection
approach, we determined a ranking of the biomarkers within
each platform. Figure 2 displays the ranking of the first few
Table 2 Associations of each biomarker (considered separately) with final eGFR
Biomarker Basic covariates Basic covariates + ACR Full covariates
β (95% CI) p value β (95% CI) p value β (95% CI) p value
Serum biomarkers
TNFR1 −0.20 (−0.24, −0.17) 1.4 × 10−35 −0.17 (−0.20, −0.14) 3.0 × 10−24 −0.12 (−0.16, −0.09) 3.2 × 10−14
KIM-1 −0.18 (−0.21, −0.16) 4.8 × 10−35 −0.14 (−0.17, −0.11) 1.7 × 10−19 −0.14 (−0.17, −0.11) 7.0 × 10−20
CD27 −0.17 (−0.20, −0.14) 7.1 × 10−29 −0.14 (−0.17, −0.11) 1.8 × 10−18 −0.11 (−0.13, −0.08) 1.4 × 10−12
α-1-microglobulin −0.12 (−0.14, −0.09) 1.1 × 10−17 −0.08 (−0.11, −0.06) 7.4 × 10−10 −0.07 (−0.10, −0.05) 2.9 × 10−08
Syndecan 1 −0.12 (−0.15, −0.09) 5.1 × 10−17 −0.09 (−0.12, −0.06) 1.0 × 10−10 −0.07 (−0.10, −0.04) 1.0 × 10−07
Thrombomodulin −0.10 (−0.13, −0.07) 2.0 × 10−11 −0.07 (−0.10, −0.05) 2.6 × 10−07 −0.05 (−0.07, −0.02) 3.1 × 10−04
Cystatin C −0.05 (−0.07, −0.02) 5.9 × 10−04 −0.03 (−0.06, 0.00) 2.8 × 10−02 −0.03 (−0.06, −0.01) 1.3 × 10−02
Matrix metalloproteinase-8 −0.04 (−0.07, −0.01) 2.6 × 10−03 −0.03 (−0.06, −0.01) 1.0 × 10−02 −0.02 (−0.04, 0.00) 1.1 × 10−01
Clusterin 0.01 (−0.02, 0.04) 4.5 × 10−01 0.02 (−0.01, 0.04) 2.9 × 10−01 0.00 (−0.02, 0.03) 7.9 × 10−01
Urine biomarkers
EGF/MCP-1 ratio 0.16 (0.13, 0.19) 1.7 × 10−27 0.12 (0.09, 0.15) 6.1 × 10−15 0.10 (0.07, 0.13) 1.1 × 10−12
MCP-1 −0.10 (−0.13, −0.08) 2.2 × 10−14 −0.06 (−0.09, −0.04) 4.6 × 10−06 −0.07 (−0.09, −0.04) 4.8 × 10−07
IL-8 −0.07 (−0.10, −0.05) 6.5 × 10−07 −0.03 (−0.06, 0.00) 5.3 × 10−02 −0.02 (−0.05, 0.01) 1.5 × 10−01
EGF 0.07 (0.04, 0.10) 1.0 × 10−06 0.07 (0.04, 0.10) 6.3 × 10−06 0.05 (0.02, 0.07) 1.1 × 10−03
EGF receptor −0.05 (−0.08, −0.03) 1.0 × 10−04 −0.01 (−0.04, 0.01) 3.6 × 10−01 −0.01 (−0.03, 0.02) 6.1 × 10−01
IL-18 −0.05 (−0.08, −0.02) 5.0 × 10−04 −0.01 (−0.03, 0.02) 7.0 × 10−01 0.00 (−0.03, 0.02) 7.1 × 10−01
IL-6 −0.04 (−0.07, −0.01) 2.6 × 10−03 0.00 (−0.02, 0.03) 7.8 × 10−01 0.00 (−0.02, 0.03) 7.2 × 10−01
Macrophage inflammatory
protein-1 β
−0.04 (−0.07, −0.01) 5.2 × 10−03 0.00 (−0.02, 0.03) 8.4 × 10−01 0.00 (−0.02, 0.03) 8.4 × 10−01
Amphiregulin −0.04 (−0.06, −0.01) 1.0 × 10−02 0.00 (−0.03, 0.02) 7.5 × 10−01 0.01 (−0.02, 0.03) 6.6 × 10−01
Placenta growth factor −0.03 (−0.05, 0.00) 5.3 × 10−02 0.00 (−0.02, 0.03) 8.2 × 10−01 0.00 (−0.02, 0.03) 9.5 × 10−01
IL-4 −0.02 (−0.05, 0.00) 8.2 × 10−02 0.01 (−0.02, 0.03) 6.9 × 10−01 0.02 (−0.01, 0.04) 2.3 × 10−01
Epiregulin −0.02 (−0.05, 0.00) 8.6 × 10−02 0.01 (−0.02, 0.04) 4.7 × 10−01 0.01 (−0.02, 0.03) 4.8 × 10−01
Heparin-binding EGF-like
growth factor
−0.02 (−0.05, 0.01) 1.2 × 10−01 0.01 (−0.02, 0.03) 6.5 × 10−01 0.02 (−0.01, 0.04) 2.2 × 10−01
Regression coefficients are per unit SD of Gaussianised biomarker
Basic clinical covariates: age, sex, diabetes duration, study day eGFR, length of follow-up
Full clinical covariates: age, sex, diabetes duration, study day eGFR, length of follow-up, ACR, BMI, diastolic BP, systolic BP, HbA1c, HDL-cholesterol,
total cholesterol, smoking status, weighted average of historical eGFR
Table 3 Cross-validated performance of models for prediction of final eGFR
Model Basic covariates Basic covariates + ACR Full covariates
ΔLoglik r2 (95% PI) ΔLoglik r2 (95% PI) ΔLoglik r2 (95% PI)
Clinical covariates only – 0.702 (0.700, 0.704) – 0.722 (0.720, 0.724) – 0.758 (0.756, 0.761)
Serum biomarkers 120.9 0.743 (0.740, 0.746) 73.3 0.746 (0.743, 0.749) 56.3 0.775 (0.772, 0.777)
Urine biomarkers 54.2 0.721 (0.718, 0.724) 21.6 0.729 (0.726, 0.732) 19.2 0.764 (0.761, 0.767)
Basic and full clinical covariates are listed in the footnotes to Table 2
ΔLoglik, difference in test log-likelihood (natural logarithm) with respect to the model containing only clinical covariates; PI, posterior uncertainty
interval
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serum biomarkers when predicting final eGFR or progression
to <30 ml min−1 [1.73 m]−2, starting from the basic set of
covariates. We also treated baseline ACR as another biomark-
er (Fig. 2b,d). For final eGFR, TNFR1 and KIM-1 together
account for more than 75% of the information contained in the
whole set of serum biomarkers independently of ACR, with
clusterin and α-1-microglobulin making a small contribution
beyond this (Fig. 2a,b). For progression to <30 ml min−1
[1.73 m]−2, KIM-1 and CD27 (which is very strongly corre-
lated with TNFR1) contain most of the predictive information
(Fig. 2c). KIM-1, CD27 and syndecan 1 also contribute to the
total prediction on top of ACR (Fig. 2d).
Discussion
The key findings from this study across the range of CKD
stages were that serum biomarkers improve the prediction of
future eGFR and progression to <30 ml min−1 [1.73 m]−2
beyond baseline eGFR. As in our past studies [11, 21, 22], a
large number of the biomarkers evaluated showed highly
significant associations with eGFR and its decline. However,
almost all of the predictive information could be obtained
using just a few of these intercorrelated biomarkers. Here,
we found KIM-1 measured by SIMOA assay and either
CD27 or TNFR1 to contain most of the predictive informa-
tion. CD27 and TNFR1 are very highly correlated (r = 0.80)
and are both members of the TNF superfamily and therefore
likely interchangeable as predictive biomarkers. Beyond
these, there is some predictive information in syndecan-1,
clusterin or α-1-microglobulin.
An important emphasis of the study reported here was a
comparison of biomarkers with the performance of the widely
accepted measurement ACR. In this regard, we found that a
parsimonious panel of serum biomarkers performed better
than ACR for predicting eGFR and eGFR progression to
Table 4 Cross-validated performance of models for prediction of final eGFR being <30 or <45 ml min−1 [1.73 m]−2, overall and stratified by
albuminuric status at study day
Model Basic covariates Basic covariates + ACR Full covariates
ΔLoglik AUC (95% PI) Λ ΔLoglik AUC (95% PI) Λ ΔLoglik AUC (95% PI) Λ
Final eGFR<30 (n = 1627, 41 events)
Clinical covariates only – 0.876 (0.858, 0.890) 2.18 – 0.911 (0.895, 0.924) 3.23 – 0.929 (0.912, 0.943) 3.93
Serum biomarkers 35.3 0.953 (0.940, 0.965) 4.06 11.2 0.952 (0.939, 0.965) 4.08 0.8 0.940 (0.920, 0.956) 4.28
Urine biomarkers 3.2 0.879 (0.852, 0.901) 2.52 −13.8 0.892 (0.866, 0.913) 2.84 −0.2 0.929 (0.912, 0.943) 3.92
Final eGFR<30 in normo-/microalbuminuric (n = 1571, 18 events)
Clinical covariates only – 0.788 (0.737, 0.836) 1.32 – 0.793 (0.740, 0.845) 1.43 – 0.818 (0.757, 0.873) 2.10
Serum biomarkers 9.3 0.861 (0.807, 0.909) 2.20 7.3 0.856 (0.799, 0.908) 2.14 −2.6 0.815 (0.760, 0.871) 2.20
Urine biomarkers −0.3 0.786 (0.732, 0.840) 1.31 −1.2 0.787 (0.732, 0.840) 1.32 0.3 0.819 (0.761, 0.873) 2.10
Final eGFR<30 in macroalbuminuric (n = 56, 23 events)
Clinical covariates only – 0.750 (0.692, 0.809) 1.33 – 0.801 (0.743, 0.852) 1.95 – 0.771 (0.697, 0.843) 2.56
Serum biomarkers 4.3 0.830 (0.755, 0.896) 2.31 1.6 0.835 (0.760, 0.895) 2.33 −8.6 0.764 (0.685, 0.839) 2.46
Urine biomarkers −1.0 0.770 (0.697, 0.835) 1.45 −4.7 0.765 (0.686, 0.833) 1.41 −7.6 0.758 (0.677, 0.834) 2.24
Final eGFR<45 (n = 1573, 74 events)
Clinical covariates only – 0.840 (0.830, 0.849) 1.54 – 0.889 (0.881, 0.897) 2.31 – 0.901 (0.891, 0.911) 2.68
Serum biomarkers 33.6 0.899 (0.887, 0.911) 2.49 8.3 0.907 (0.894, 0.918) 2.59 5.4 0.914 (0.901, 0.926) 2.96
Urine biomarkers 15.3 0.879 (0.866, 0.890) 1.98 −5.5 0.890 (0.877, 0.902) 2.22 −0.3 0.901 (0.891, 0.912) 2.68
Final eGFR<45 in normo-/microalbuminuric (n = 1529, 53 events)
Clinical covariates only – 0.857 (0.843, 0.870) 1.70 – 0.866 (0.854, 0.878) 1.93 – 0.876 (0.858, 0.891) 2.33
Serum biomarkers 16.3 0.891 (0.877, 0.904) 2.31 9.9 0.890 (0.875, 0.904) 2.30 5.0 0.891 (0.872, 0.908) 2.63
Urine biomarkers −2.4 0.852 (0.834, 0.869) 1.71 −9.7 0.849 (0.831, 0.867) 1.75 −1.6 0.872 (0.851, 0.890) 2.34
Final eGFR<45 in macroalbuminuric (n = 44, 21 events)
Clinical covariates only – 0.538 (0.429, 0.640) 0.17 – 0.529 (0.416, 0.634) 0.19 – 0.561 (0.472, 0.644) 0.25
Serum biomarkers −10.1 0.510 (0.400, 0.627) 0.07 −9.3 0.512 (0.395, 0.634) 0.07 −30.1 0.536 (0.437, 0.634) 0.22
Urine biomarkers −2.7 0.541 (0.422, 0.646) 0.18 −0.1 0.540 (0.428, 0.658) 0.17 −94.1 0.479 (0.379, 0.578) −0.35
Basic and full clinical covariates are listed in the footnotes to Table 2
ΔLoglik, difference in test log-likelihood (natural logarithm) with respect to the model containing only clinical covariates; PI, posterior uncertainty
interval; Λ, expected information for discrimination in bits
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<30mlmin−1 [1.73m]−2. Indeed, serum biomarkers contained
almost double the prediction information (measured in bits)
than ACR for progression to <30 ml min−1 [1.73 m]−2. The
serum biomarkers were predictive of final eGFR in those with
starting eGFR above 90 ml min−1 [1.73 m]−2, suggesting that
they rise before ACR does and may be more sensitive to early
renal damage. Of note, the urinary biomarkers did not consis-
tently outperform ACR.
These data challenge the place of ACR in our clinical
management of people with diabetes. Most clinical guidelines
now recommend annual measurement of ACR in people with
diabetes. Our data suggest that measuring just KIM-1 and
TNFR1 or CD27 in the same sample might obviate the need
for doing a urine sample collection and then measuring ACR.
Collecting urine samples is time intensive in outpatient clinics
and many people miss out on annual screening because they
do not bring or cannot produce a urine sample. As we note
above, while in Scotland we achieve high rates of annual
eGFR measurement, ACR capture rates are much lower
[10]. Additional differences in reporting rates for ACR than
eGFR exist elsewhere, e.g. in the National Diabetes Audit in
England and Wales and in reports from Denmark [23, 24].
Clearly, further validation is required before advocating
replacing ACR. Longitudinal analyses of repeat measure-
ments of these biomarkers, for example, are needed to estab-
lish their variability and thresholds for specific risk levels
warranting clinical action (akin to the microalbuminuria
thresholds).
Replication in different cohorts across the range of
eGFR, using a variety of assay methods, and testing for
prediction of ESRD are also needed. Moreover, at the pres-
ent time these biomarkers are much more expensive to
assay than ACR and are not routinely available on many
commonly used clinically certified assay platforms. Some
may argue that ACR is also measured because it is a
biomarker of more widespread vascular disease and
mortality independently of renal function: this should also
be shown for candidate replacement serum biomarkers.
Nonetheless, at the very least our data suggest that further
studies to evaluate replacing urinary ACR with serum
biomarkers are warranted, given the logistic and predictive
advantages they may offer.
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Fig. 2 Contribution of
biomarker sets to prediction of
final eGFR (a, b) or final eGFR
<30 (c, d) when starting from a
model containing basic covariates
(age, sex, diabetes duration, study
day eGFR and length of follow-
up). Variable selection was based
on: serum biomarkers (a, c); and
serum biomarkers and ACR (b,
d). A1Micro, α-1-microglobulin;
CLU, clusterin; Cys-C, cystatin
C; MMP8, matrix
metalloproteinase-8; SDC1,
syndecan 1
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Serum biomarkers might be useful on top of ACR rather
than instead of it. In regard to the latter, it is important to note
that these biomarkers also added to the prediction of final
eGFR or progression even when ACR was included in the
model. Furthermore, they also predicted progression to
<30 ml min−1 [1.73 m]−2 in those normoalbuminuric or
microalbuminuric at baseline, and did so independently of
ACR. This suggests they may be useful even when ACR
has already been measured and found not to be in the
macroalbuminuric range. Once macroalbuminuria has been
detected, however, they do not improve prediction further.
Such people with macroalbuminuria would in any case be
managed uniformly as a high-risk group, and it is questionable
whether any further risk discrimination among them would
alter clinical practice.
Our study has used eGFR and its progression to <30 and
<45 ml min−1 [1.73 m]−2 as endpoints. Of course, as we
recently reviewed, creatinine-based eGFR is itself an imper-
fect measure of underlying GFR, especially at early stages of
renal function decline [3]. Ideally, biomarker studies would
also evaluate prediction of harder endpoints such as ESRD.
However, to evaluate prediction from early stages of renal
function decline to ESRD requires large unselected cohorts
of people with type 1 diabetes to be followed for many years
for sufficient ESRD endpoints to accrue. Such studies are
logistically challenging and usually have very few ESRD
endpoints in those with eGFR >60 ml min−1 [1.73 m]−2 at
baseline [25, 26]. Furthermore, it requires that we generalise
from samples taken several decades ago to the contemporary
state of diabetes. Therefore, studies such as ours with interme-
diate endpoints are also needed. It should be noted that the
imprecision with which eGFR quantifies underlying GFR
means that power to detect biomarker associations is reduced
rather than false positive associations being detected. Our
study will accrue ESRD endpoints as we continue follow-
up, eventually allowing associations with this endpoint to be
confirmed. Further analyses will also attempt to disentangle
the contribution of prediction of intervening acute renal failure
events to overall prediction of decline as events accrue.
Another limitation of our study is that we were not able to
assess incremental prediction on top of the validated kidney
failure risk equation [27], as calcium and phosphate data were
not available in most participants.
A key strength of our study was the deliberate use of
samples from a wide range of starting eGFR. Another key
strength of our study is the use of advanced statistical methods
that avoid over-optimistic assessments of prediction. These
include cross-validation and use of penalised models that
account for the high number of analytes being evaluated and
can better handle correlations between predictors.
Conclusions In summary, a parsimonious panel of serum
biomarkers measurable along with creatinine may outperform
ACR for predicting renal disease progression from early CKD
stages in type 1 diabetes, and with further development might
obviate the need for urine testing.
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